sification II chronic heart failure (CHF) as the result of ischemic dilated cardiomyopathy and in healthy control subjects with similar general characteristics.
Furthermore, because a recent report observed that sildenafil citrate induces an increase of sympathetic activity, 12 we then also investigated drug-induced changes in arterial pressure, heart rate, and autonomic control. Autonomic nervous system control was assessed with spectral analysis of RR [13] [14] [15] and arterial pressure variability. 13, [15] [16] [17] [18] 
Methods

Study subjects
For this study, we selected patients who had mild CHF (NYHA classification II) as the result of ischemic dilated cardiomyopathy and healthy volunteer controls from among staff in the clinic. Patients were excluded if they had had a myocardial infarction within 6 months before enrollment or had recently undergone revascularization procedures or coronary angioplasty. Patients had stable symptoms of heart failure; none had been hospitalized, had manifested worsening symptoms, or had changed therapy during the past 3 months. None of the patients had atrial fibrillation, frequent extrasystole (1 extrasystole per minute was permitted), branch block, or other arrhythmias likely to interfere with assessments.
All subjects underwent a complete history, physical examination, routine laboratory investigation, electrocardiography, 2-dimensional echo-Doppler scan study of the vessels, and echocardiography. During echocardiography, data were obtained to determine the left ventricular mass index and ejection fraction. Patients with CHF were taking standard medications for heart failure, including enalapril (10 mg/day), furosemide (25 mg/day), spironolactone (25 mg/day), carvedilol (12.5 mg/day), and acetylsalicylic acid. Those taking nitrates or other drugs that can interfere with sildenafil citrate plasma concentrations were excluded. 1 All participants gave their informed consent to the procedures, and the local ethics committee approved the study. The study complied with the ethical rules for human experimentation stated in the Declaration of Helsinki.
Study protocol and data acquisition
Because the aim of the study was to assess cardiac repolarization and autonomic control, in single-blind design, after administration of placebo or a 50-mg tablet of sildenafil citrate, all subjects underwent a 12-lead electrocardiographic recording at a speed of 50 mm/s and simultaneous beat-to-beat recording of the electrocardiographic trace in the second lead (Telemetria Mortara Rangoni, Bologna, Italy), of systolic blood pressure (SBP; Finapres, Ohmeda, Englewood, NJ), and respiratory frequency (strain-gauge belt). This recording lasted 10 minutes. The first recording was used for measurement of QT duration and dispersion, and the second for autonomic assessment and determination of QT dynamics. Each session comprised the 2 assessments: after placebo and after drug. To avoid possible changes in the electrode placement, adhesive electrodes were used. They were placed when the study began and removed only when it ended. The 12-lead electrocardiography was recorded 50 minutes after administration of drug or placebo, and the 10-minute recording began 55 minutes after administration of drug or placebo. During the 10-minute recording, subjects breathed at a frequency of 20 breaths/min (0.33 Hz) in time with a metronome.
The 3 analogic signals (electrocardiography, SBP, and respiratory frequency) were acquired simultaneously and digitally converted with a custom-designed card (Keithley Metrabyte-DAS 1200 Series, Cleveland, Ohio) at a sampling frequency of 500 Hz per channel with 12-bit precision. For recognition and measurement of the RR and QT interval, SBP, and respiratory rate we used a software program developed in our laboratory on the basis of an automated derivative/threshold algorithm. To calculate the QT interval and to make the end of the T wave easier to identify, we used a software program on the basis of the algorithm for quantification of beatto-beat fluctuations in QT interval variability proposed by Berger et al. [8] [9] [10] [11] From both 10-minute recordings, we selected a stationary continuous 256-beat segment (Figure 1 ) for the determination of RR, QT, and SBP variability (Figure 1 ).
RR and systolic blood pressure variability
For RR and SBP, we calculated the following spectral components: high-frequency (HF) component, from 0.15 to 0.42 Hz; and low-frequency (LF) component: from 0.03 to 0.15 Hz (Figure 2) . The spectral components were transformed into their natural logarithm (ln) and into normalized units (normal-
Figure 1
Simultaneous 256-beat recordings of systolic blood pressure (SBP), of heart rate expressed as RR interval (RR), QT interval (QT), and respiratory frequency (RESP). Top panel, After placebo; lower panel, after oral sildenafil citrate. After sildenafil citrate administration, SBP decreased (from mean 114 mm Hg during placebo to 102 mm Hg after sildenafil citrate). Mean RR intervals shortened (from 720 ms after placebo to 695 ms after sildenafil citrate). Mean QT interval lengthened (from 315 ms after placebo to 324 after sildenafil citrate).
ized unit LF = LF/total Power -very-low-frequency × 100; normalized unit HF = HF/total Power -very-low-frequency × 100). 14, 15, 19, 20 Last, we calculated the ratio between LF and HF powers of RR variability (LF/HF). 14, 15, [19] [20] [21] [22] Software for data acquisition and storage and for spectral analysis were designed and produced by our research group and have been described in detail elsewhere. 15, 19, 20 The α index was calculated by dividing the square root of the spectral density of the heart rate by the square root of the corresponding spectral density of arterial pressure, as described by Robbe et al 23 and later by other investigators [15] [16] [17] [18] 24, 25 :
The coherence function of the various spectral components then was estimated. Coherence expressed the fraction of power at a given frequency in either time series that could be explained as a linear transformation between the 2 signals. Recordings showing <0.5 coherence in LF and HF 16 between the SBP and RR variability signals were discarded. The phase of systolic pressure and RR interval relation was -45°± 5°in LF and -30°± 7°in HF. These results suggest that systolic pressure variations precede RR interval variations. 18 Spectra of the respiratory trace were analyzed on the signal sampled once every cardiac cycle. These spectra were used as a reference to identify heart rate oscillations caused by respiratory sinus arrhythmia. The RR interval and respiratory signal recordings were also used for cross-spectral analysis. The software program automatically calculated the respiratory frequency for each cycle.
QT interval dynamic and variability index
QT interval was calculated from Q wave to the end of the T wave. From stationary 256-beat segments recorded before and after drug administration, we calculated the mean (QT m ) and variance (QT v ) of the QT intervals and the QT-RR slope (Figure 3) . QT v and QT m also were used to calculate the QTVI (Figure 4 ) with the following formula: QTVI = log 10 [8] [9] [10] [11] where RR m is the mean and RR v is the variance of the 256 RR intervals.
The 256 QT segments also were analyzed spectrally ( Figure  4 ) and with cross-spectral analysis with RR. The last variable determined was coherence, calculated from the spectral region between 0 and the end of the respiratory peak ( Figure 4 ).
Measurement of QT intervals and dispersion
The duration of the QT interval was measured at each lead of the 12-lead surface electrocardiogram for 2 consecutive cycles. Interval dispersion was calculated with the Perkiomaki method. 26, 27 QT intervals were measured from the onset of the QRS to the end of the T wave with a tangential method. When U waves were present, the tangent was also used to measure the QT to the nadir of the curve between the T and U waves. Variables were measured manually by a trained operator blinded to each subject's clinical and spectral data. Bazett's formula was used to obtain QT intervals corrected for heart rate (QT c ). QT c dispersion was defined as the difference between the respective maximum and minimum QT c , and the mean value of 2 consecutive cycles was calculated. Interobserver measurement error was avoided with measurements QT-RR slope after placebo and after sildenafil citrate in representative subject. Oral sildenafil citrate in this subject increased slope.
yielded by the same trained operator. Intraobserver and measurement errors of QT c dispersion were defined.
Statistical analysis
All data were evaluated with database SPSS-PC+ (SPSS-PC+ Inc, Chicago, Ill). All results are expressed as mean ± standard error. One-way analysis of variance was used to compare the general characteristics and other data, including QTVI data, in the 2 groups.
Paired t test was used to evaluate the differences between the data measured during placebo or drug. A P value of <.05 was considered to indicate statistical significance.
Results
No significant differences were found between patients with mild CHF and healthy subjects for age, sex, body mass index, or other general characteristics. The only variables that differed between groups were the ejection fraction and QT duration, dispersion, and variability (Table) .
Oral sildenafil citrate significantly lowered the mean beat-to-beat SBP in both groups (in patients with CHF, from 107 ± 3 to 100 ± 2 mm Hg; in controls, from 112 ± 2 to 103 ± 2 mm Hg; P <.05). The percentage reduction was slightly, although not significantly, larger in patients (6% ± 2% and 8% ± 2%). Conversely, sildenafil citrate had no effect on diastolic blood pressure in patients with CHF but slightly reduced this variable in controls (P <.05).
Sildenafil citrate increased the mean heart rate in both groups (in patients with CHF by 13% ± 3% and in controls by 8% ± 3%; P <.05). None of the men had adverse reactions that could be attributed to sildenafil citrate.
RR and systolic blood pressure variability
The spectral analysis of RR variability showed that after sildenafil citrate and after placebo men with CHF had lower variability (variance) and total spectral power (TP) than did controls (P <.05). By contrast, their LF values, expressed as the ln and in normalized units, were higher than those of controls (P <.05). HF was invariably significantly lower in patients with CHF ( Figure 5 ). By contrast, the LF/HF ratio was higher in patients with CHF (P <.05; Figure 6 ).
In subjects with CHF and controls, oral sildenafil citrate induced a significant reduction in HF, expressed in ln (subjects with CHF: from 4.04 ± 0.14 ln ms 2 to 3.43 ± 0.16 ln ms 2 ; P <.001; controls: from 5.61 ± 0.44 ln ms 2 to 4.98 ± 0.32 ln ms 2 ; P <.05; Figure 5 ) and in normalized units (P <.05). In subjects with CHF but not in controls, it also significantly increased the LF/HF ratio (from 1.3 ± 0.12 to 1.89 ± 0.16; P <.001; Figure 6 ) and LF expressed in normalized units (P <.05). Both groups had higher LF power of SBP, expressed in the absolute form (mm Hg 2 ) and in normalized units, after sildenafil citrate (P <.001). α LF and α HF were both lower in patients. In both groups, the drug also decreased the α HF index (patients with CHF: from 5.81 ± 0.75 ms/mm Hg to 4.50 ± 0.45 ms/mm Hg; P <.05; controls: from 15.88 ± 3.88 ms/mm Hg to 10.80 ± 2.4 ms/mm Hg; P <.05).
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Figure 4
QT interval spectra recorded after placebo and after sildenafil citrate. QT variability index (QTVI) was increased after sildenafil citrate.
Subjects with
Control heart failure subjects P Variables (n = 10) (n = 10) value 
Table I. General characteristic of study subjects
No significant changes were found for coherence between SBP and RR signals after placebo or after drug. No subjects were excluded because of reduced signal coherence, but men with CHF had significantly lower coherence for these 2 variables (P <.05)
QT interval dynamic and variability index
Whereas QT m was significantly longer in patients with CHF than in control subjects (P <.001), QT v values in the 2 study groups overlapped. After oral sildenafil citrate, in patients with CHF, QT m increased (from 388 ± 4 ms to 396 ± 3 ms; P <.05) as did QT v (from 47 ± 2 ms to 55 ± 2 ms; P <.001); whereas in healthy subjects, QT m decreased (from 329 ± 4 ms to 326 ± 4 ms; P <.05) and QT v increased (from 47 ± 5 ms to 55 ± 4 ms; P <.05).
Patients with CHF invariably had higher regression slope values than did control subjects (P <.05; Figure  7 ). Their slope values also increased significantly after sildenafil citrate (from 0.09 ± 0.01 to 0.18 ± 0.01; P <.001), whereas those of control subjects remained practically unchanged (from 0.05 ± 0.01 to 0.05 ± 0.01; not significant; Figure 7) .
Patients with CHF invariably had higher QTVI values than did control subjects (Figure 8 ). Oral sildenafil citrate increased the QTVI in both groups (subjects with CHF: from -0.45 ± 0.07 to -0.27 ± 0.07; P <.001; control subjects: from -1.20 ± 0.08 to -0.78 ± 0.14; P <.001; Figure 8) .
No significant changes were found between QT and RR signal coherence after drug and after placebo.
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Figure 5
Changes in natural logarithm (ln) high-frequency spectral component (HF) of RR variability in men with chronic heart failure (CHF) and control subjects. In this and subsequent box plots, central line represents median distribution, each box spans from 25th to 75th percentile points, and error bars extend from 10th to 90th percentile points (with analysis of variance and paired t test). Note that men with CHF after placebo (P <.05) and after oral sildenafil citrate (P <.001) invariably had lower ln of HF. In both groups, drug significantly reduced this spectral component.
Figure 6
Changes in natural logarithm low-frequency/high-frequency spectral component (LF/HF) of RR variability in men with chronic heart failure (CHF) and control subjects (with analysis of variance and paired t test). Note that men with CHF had higher natural logarithm LF/HF after placebo (P <.05) and after oral sildenafil citrate (P <.05). In men with CHF, sildenafil citrate induced significant increase in these spectral indices (with analysis of variance and paired t test).
Figure 7
Changes in QT-RR slope in patients with chronic heart failure (CHF) and control subjects (with analysis of variance and paired t test). Note that in men with CHF after placebo (P <.05) and after oral sildenafil citrate (P <.001) QT-RR slope was always higher in men with CHF than in control subjects. In addition, drug caused significant increase in this variable but did so only in men with CHF.
Patients had significantly lower coherence for this pair of signals (P <.05).
QT interval dispersion
QT values remained statistically unchanged after oral sildenafil citrate. Notably, neither the duration of the various QT and QT c measures in the various leads nor QT and QT c dispersion changed. Intraobserver variability was 3 ms.
Discussion
Our data in this study show that oral sildenafil citrate induces changes in some of the variables that dynamically assess cardiac repolarization. Notably, in men with mild CHF, it increased the QT-RR slope and the QTVI. Yet, it left the QT interval and QT dispersion unchanged. This result is hardly surprising insofar as both these QT variables predominantly reflect structural changes (including hypertrophy, dilatation, infarction, and genetically induced alterations in potassium or sodium channels), 4, [25] [26] [27] [28] [29] whereas the dynamic tests measure temporal changes and therefore mainly depend on altered cardiovascular autonomic control. 5, [30] [31] [32] [33] [34] [35] Accordingly, both tests yielded higher baseline values in patients with CHF than in healthy subjects. Hence, the changes in the duration of cardiac repolarization induced by the I kr blockage, which can induce a prolonged pharmacologic QT, probably occur at higher blood concentrations (possibly 100-fold higher) than those achieved by the dose normally needed to induce an erection and used in this study (50 mg). 3 Presumably, the concentrations used in vitro could also induce in vivo changes in the duration of cardiac repolarization and hence in QT dispersion.
Oral sildenafil citrate induced changes in autonomic cardiovascular control that might cause secondary alterations in cardiac repolarization. In particular, the drug exerted a mild systemic vasodilatory action that slightly lowered pressures, thus causing a reflex increase in the heart rate. The increased heart rate could depend either on a drug-induced reduction of sinus vagal modulation or increased sympathetic modulation or on both phenomena. Evidence that healthy subjects reduced vagal modulation alone comes from the reduction in HF measured in the absolute form and in normalized units ( Figure 5) . HF, especially when obtained with controlled breathing, provides a reliable index of parasympathetic sinus modulation. [13] [14] [15] [16] [17] [18] [19] [20] 28 Further evidence confirming its reliability came in this study from the reduction in α HF, a spectral index of baroreflex sensitivity that correlates reasonably well with baroreflex sensitivity determined with the phenylephrine method. 17, 24, 25, 36 Conversely, in men with CHF, we also observed a reduction in HF RR after sildenafil citrate and a significant increase in the LF/HF ratio. This variable, is generally, though not unanimously, [35] [36] [37] [38] considered a measure of increased sympathetic activity. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 26 This result is confirmed also by the increased LF of RR measured in normalized units. With these experimental circumstances, the use of normalized units is more appropriate because normalization reduces the influence of TP (see Methods), 14, 19 namely, the total RR variability expressed as variance. Thus, by reducing the mean RR interval (tachycardia), oral sildenafil citrate reduced TP and thus lowered LF and HF. But in relative terms (normalized units), LF tended to increase. These data suggest that, in men with CHF, as sinus vagal modulation diminishes sinus sympathetic modulation increases. Besides, the increased LF of SBP indicates a drug-induced increase in vascular sympathetic activity. Hence, in men with mild CHF, who, despite chronic carvedilol therapy at small doses, had increased baseline sympathetic activity linked to their disease, oral sildenafil citrate further increased sinus sympathetic modulation, thus resulting in vagal withdrawal, and concomitantly lowered baroreflex sensitivity. A plausible reason for the finding that sildenafil citrate increased sympathetic activity-already high in persons with heart failure-is that the men we studied had only mild CHF. Men in higher NYHA classifications, hence with lower ejection fractions, would probably be unable to augment LF power. 36, [39] [40] [41] Despite the carvedilol-induced α adrenergic receptor inhibition and enalaprin-induced formation of angiotensin II in patients, sildenafil citrate induced a similar systemic vasodilatory effect in the 2 groups.
Figure 8
QT variability index (QTVI) changes in patients with chronic heart failure (CHF) and control subjects (with analysis of variance and paired t test). Note that after placebo (P <.001) and after oral sildenafil citrate (P <.001) QTVI was always higher in patients with CHF. Oral sildenafil citrate significantly increased this variable in both groups.
Hence, at these plasma concentrations, the drug is hemodynamically tolerated. Furthermore, the pressureinduced effects in patients with CHF had no influence on diastolic blood pressure, probably because these patients' peripheral resistance is modulated by the use of carvedilol and enalapril but mainly by the autonomic nervous system. These autonomic changes, probably more than the effect of the I kr blockage, induce a dynamic change in cardiac repolarization that increases the QT-RR slope and QTVI. The autonomic nervous system response characterized by vagal withdrawal along with enhanced sympathetic activity and the increase in the QT-RR slope and QTVI, providing evidence of a temporal inhomogeneity in cardiac repolarization, are risk factors for sudden death. [5] [6] [7] [8] [9] [10] 29 More important, the increased QTVI correlates with an increase in the severity of CHF 8 and with the presence of malignant tachycardias and ventricular arrhythmias. 9 Our data need further clarification. In the healthy men we studied, sildenafil citrate did not alter both indexes of ventricular repolarization in a similar manner. Whereas the QTVI significantly increased, the QT-RR slope remained unchanged after drug administration. The most likely explanation for this discrepancy is that the QTVI increases also as a function of the reduction in RR variance (see Methods), an indirect index of altered autonomic control, [8] [9] [10] [11] whereas the QT-RR slope is influenced by RR variance. In other words, the sildenafil citrate-induced reduction in RR variance could increase the QTVI. QT dynamics expressed as the QT-RR slope would be altered only in persons with severely defective autonomic control, such as those with CHF. In healthy subjects, the vagal reduction induced at a normal sildenafil citrate dose leaves the QT-RR slope unchanged.
Finally, we consider that men wishing to take sildenafil citrate, especially those with CHF and pathophysiologic conditions involving the autonomic nervous system, including hypertension, 15, [18] [19] [20] 28 obesity, 42, 43 anxiety neurosis, 20, 28, 44, 45 or aging, 19, [45] [46] [47] [48] [49] should undergo dynamic assessment of cardiac repolarization. Dynamic monitoring of the electrocardiogram during sexual activity after a sildenafil citrate-induced erection could be extremely useful to assess the risks of sildenafil citrate therapy.
